早期乳腺癌骨保护治疗  

Bone protection therapy in early breast cancer

作　　者：盛笑 石晓琦 成金罗[1] SHENG Xiao;SHI Xiao-qi;CHENG Jin-luo(Changzhou No.2 People s Hospital,Changzhou 213000,Jiangsu,China)

机构地区：[1]南京医科大学附属常州市第二人民医院,江苏常州213000

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2020年第3期280-286,共7页Chinese Journal Of Osteoporosis And Bone Mineral Research

摘　　要：乳腺癌是全球女性中最常见的恶性肿瘤,也是中国最常见的恶性肿瘤。大多数乳腺癌患者表现为雌激素或孕激素受体阳性。内分泌治疗是激素受体阳性乳腺癌患者的常用治疗方法。而内分泌治疗与骨损失及骨折风险增加相关。目前对乳腺癌内分泌治疗所致的骨丢失尚无令人满意的防治措施,本文旨对激素受体阳性的早期乳腺癌患者治疗过程中骨量减少或骨质疏松的发生机制及目前早期乳腺癌中预防和治疗骨质疏松药物的进展做一综述。Breast cancer is the most common maliganacy in women worldwide,including China.Most breast cancer patients show positive estrogen or progesterone receptors.Endocrine therapy is a commonly used treatment for hormone receptor-positive breast cancer patients.Endocrine therapy is associated with increased bone loss and increased risk of fractures.At present,there are no satisfactory prevention and treatment measures for bone loss caused by endocrine therapy of breast cancer.This article aims to explore the mechanism of bone loss or osteoporosis during the treatment of hormone receptor positive early breast cancer patients and its prevention and treatment.

关 键 词：乳腺癌 内分泌治疗 骨保护 骨质疏松 

分 类 号：R681[医药卫生—骨科学]